Boston Scientific (BSX) Drops 5% Ahead of Q1 Earnings Report

Recent Developments

Boston Scientific Corporation (NYSE: BSX) is set to report first-quarter earnings before the market opens on Wednesday. The medical device maker enters the report under pressure, with shares declining sharply in Monday's session and appearing among the notable S&P 500 movers for the day.

Ahead of the results, Truist cut its price target on BSX to $90 from $92 on April 15 while maintaining a Buy rating. According to Yahoo, the adjustment came as part of a broader research note previewing fiscal Q1 results across the healthcare sector. Truist flagged Boston Scientific as one of the most oversold healthcare stocks.

Separately, a report from EY highlighted trends shaping the medtech industry. Original equipment manufacturers continue to prioritize high-growth segments such as pulsed-field ablation (PFA), an area where Boston Scientific has been an active participant. The EY analysis also noted that geopolitical conflict in the Middle East is weighing on IPO activity across the broader medtech space.

Financial Snapshot

BSX closed the session at $60.99, down $3.24 or 5.04% from the previous close of $64.23. The stock is now trading near the bottom of its 52-week range of $60.59 – $109.50, sitting just $0.40 above its 52-week low.

Specific quarterly financial results are pending Wednesday's pre-market release. Investors and analysts will be watching for updates on revenue growth across the company's key segments, margin trends, and any commentary on the impact of tariffs or supply-chain dynamics on its global operations.

Wall Street View

Truist's recent price target reduction to $90 from $92 represents the most specific analyst action captured in the latest data. Even at the reduced target, it implies roughly 48% upside from Monday's closing price.

The broader analyst consensus remains firmly positive. As of April 1, the recommendation breakdown shows 13 Strong Buy ratings, 25 Buy ratings, 3 Hold ratings, and zero Sell or Strong Sell ratings — a total of 41 covering analysts. That is largely consistent with the prior month's distribution, which showed 14 Strong Buy, 23 Buy, and 3 Hold ratings. No analyst currently recommends selling the stock.

Key Takeaways

• Boston Scientific shares fell 5.04% to $60.99, hovering just above the 52-week low of $60.59, ahead of Wednesday's Q1 earnings report.
• Truist lowered its price target on BSX to $90 from $92 but kept a Buy rating, citing the stock as one of the most oversold names in healthcare.
• Wall Street consensus remains overwhelmingly bullish, with 38 out of 41 analysts rating BSX a Buy or Strong Buy and no Sell ratings on record.
• Industry trends, including growing investment in pulsed-field ablation technology, could factor into management's forward guidance when results are released Wednesday.